Skip to main content
MyDeficiencies

Ezetimibe

Cholesterol Absorption Inhibitor

Also sold as Zetia.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Ezetimibe blocks the NPC1L1 sterol transporter in the intestinal brush border, the same transporter that helps move dietary cholesterol, plant sterols, and fat-soluble vitamins into the enterocyte inside mixed micelles. That shared pathway is a genuine, named mechanism, unlike most statins, which act after absorption in the liver. But mechanism is not outcome: the manufacturer's own 113-patient trial found no clinically meaningful change in plasma vitamin A, D, or E, and a separate placebo-controlled trial in 51 vitamin D-deficient adults found no significant effect of five days of ezetimibe on vitamin D absorption after a cholecalciferol challenge. The one place the mechanism does show up clinically is vitamin K, and only in a bounded subgroup: patients already on warfarin, where adding ezetimibe is associated with a measurable rise in INR and a documented in-vitro block of NPC1L1-mediated vitamin K1 uptake. That is a monitoring flag for anticoagulated patients, not a general vitamin K deficiency claim.

cholesterol absorption inhibitor (NPC1L1 blocker) · ATC C10AX09 · also sold as Zetia · reviewed September 5, 2026, expanded September 10, 2026. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Ezetimibe in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
at least one Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, defined subgroup, or functional rather than circulating marker).
Yellow — Low
mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Vitamin K

Orange — Moderate

See study details

In patients already stabilized on warfarin, adding ezetimibe is associated with a measurable rise in INR, consistent with reduced intestinal vitamin K1 absorption; this is a monitoring flag for that specific subgroup, not a general vitamin K deficiency claim for the ezetimibe-treated population.

Full detail and limits

What the grade means here: at least one Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, defined subgroup, or functional rather than circulating marker). orange · anticoagulated subgroup only

Limits on what this shows

  • Key negative/null findings: An earlier controlled study in 12 healthy volunteers found no significant effect of ezetimibe on warfarin's own pharmacokinetics or on prothrombin time, indicating the interaction is not a simple drug-drug pharmacokinetic effect and may depend on baseline vitamin K intake, dietary status, or concurrent statin therapy.
  • At-risk subgroups: Patients on any vitamin K antagonist, especially when a statin is also being started or adjusted.

Regulatory status

Label directs that INR be monitored when ezetimibe is started in a patient already receiving warfarin, based on postmarketing reports of elevated INR.

Population evidence

Retrospective single-center cohort, 101 outpatients already on warfarin who started ezetimibe (Kitasato University, 2007-2015). Mean PT-INR rose from 1.96 (±0.45) to 2.20 (±0.61) after ezetimibe was added (p<0.001); 71 of 101 patients showed an increase; 9 required a warfarin dose reduction; time in therapeutic INR range improved from 52% to 61% (p<0.0001). The effect was stronger with concurrent statin use.

Mechanism

Named. NPC1L1 mediates intestinal vitamin K1 uptake; human NPC1L1-expressing cells show significantly higher vitamin K1 uptake activity than control cells, and that uptake is inhibited by ezetimibe in vitro, providing a direct biochemical link to the clinical INR finding.

Counter-evidence held on record

The original 2002 pharmacokinetic study (12 healthy adults, no anticoagulant instability at baseline) found no significant ezetimibe-warfarin interaction on standard PK or PT measures, a result at odds with the larger real-world retrospective cohort. This discrepancy is noted, not resolved, in the interaction literature. This is a drug-interaction and monitoring flag for anticoagulated patients, not a reason for anyone to add vitamin K or a multivitamin containing it. Increasing vitamin K intake or supplementing it would work directly against the intended anticoagulant effect and must only be adjusted by the prescriber managing the warfarin dose.

Vitamins A, D, and E

Yellow — Low

Evidence in: Tier a human data null

NPC1L1 blockade plausibly reduces absorption of any fat-soluble compound sharing the intestinal micelle/sterol pathway with cholesterol, but the direct human trials that measured vitamin A, D, and E in ezetimibe-treated patients have not found a clinically meaningful reduction.

Full detail and limits

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · mechanistic, tier a human data null

Limits on what this shows

  • Key negative/null findings: Both human studies above (label cohort n=113; RCT n=51) are null results for the vitamins they measured directly.
  • At-risk subgroups: None established specifically for vitamin A, D, or E. A separate Mendelian randomization study modeling lifelong genetically-proxied NPC1L1 inhibition (not actual ezetimibe treatment) reported an association with higher, not lower, serum calcium and vitamin A, the opposite direction from the depletion hypothesis; its primary text was blocked from direct verification, so only the reported direction, not any effect size, is carried here.

Regulatory status

Label states no clinically meaningful effect on plasma vitamin A, D, or E in a 113-patient trial (vitamin K was not evaluated in that trial).

Population evidence

Placebo-controlled RCT, 51 medical students with baseline vitamin D insufficiency (82% below 20 ng/mL): ezetimibe 10 mg/day for 5 days versus placebo, before a single 50,000 IU cholecalciferol dose. Mean rise in 25(OH)D was 8.75 (±3.74) ng/mL with ezetimibe versus 10.02 (±3.84) ng/mL with placebo, not significant (p=0.26); PTH, calcium, and albumin were also similar between groups. Separately, an active-comparator trial (simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg alone, 50 patients, 12 weeks) found 25(OH)D rose in both arms, but rose less with added ezetimibe (36.7% versus 79.1%, between-group p=0.04); this trial has no untreated control, so it shows a smaller rise alongside ezetimibe, not a fall below baseline, and cannot separate an ezetimibe effect from a dose-of-statin effect.

Mechanism

Plausible, not clinically confirmed. In Caco-2 cells, ezetimibe alters micelle structure and reduces NPC1L1-mediated uptake of vitamin E and vitamin K1 (in vitro; full text was paywalled and not independently verified beyond the published title). In mice, ezetimibe reduced uptake of deuterium-labeled vitamin D (animal; same access limitation).

Counter-evidence held on record

Every direct human measurement of vitamin A, D, or E in ezetimibe-treated patients located for this review was null or reduced-rise rather than depletion. Confounding by indication is also relevant here: hyperlipidemia patients are frequently under separate dietary counseling that could independently shift fat-soluble vitamin intake, and none of the located studies fully excluded this. This is a mechanistic hypothesis under active study, not an established deficiency. It must not be presented as "ezetimibe depletes vitamin A, D, or E" and must not be used to justify supplementation; the best-controlled human trials located found no significant depletion.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial function

Yellow — Low

Direction: reverse direction (as labelled in the source)

No study located measured ezetimibe impairing mitochondrial function in a general population; the direct human and cell-based evidence found instead shows improved mitochondrial parameters, a genuine finding that runs opposite to a "burden" hypothesis and must be reported as such.

Full detail and limits

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · reverse-direction, mechanistic

Limits on what this shows

  • Key negative/null findings: No study located found reduced mitochondrial mass, reduced ATP output, or impaired oxygen consumption attributable to ezetimibe in a general, non-oncology population. A separate in vitro/animal study found ezetimibe induces mitochondrial dysfunction specifically in colorectal cancer cells as part of a therapeutic anti-tumor mechanism (Zheng et al., 2023); this is a described oncology treatment effect in malignant cells, not evidence relevant to nutrient status in ordinary patients, and is excluded from this finding on that basis.
  • At-risk subgroups: None established for mitochondrial depletion. Patients on concurrent statin or fibrate therapy remain the labeled at-risk group for the separate, already-labeled myopathy/rhabdomyolysis adverse effect.

Regulatory status

Label lists myopathy and rhabdomyolysis (with elevated creatine kinase) as a warning, primarily in combination with a statin or fibrate. This is a documented clinical adverse effect, not a nutrient or mitochondrial-marker finding, and is not filed here as a mitochondrial deficiency claim.

Population evidence

Human, controlled trial (Hernandez-Mijares et al., Atherosclerosis, 2016): mitochondrial parameters, oxygen consumption, reactive oxygen species, and membrane potential, were measured in polymorphonuclear leukocytes of hypercholesterolemic patients treated with simvastatin, ezetimibe, or the combination; the reported direction was improved mitochondrial function, not impairment. Full quantitative results (sample size per arm, effect sizes, p-values) could not be independently verified beyond the title/abstract-level summary located; the direction is treated as reported, not the magnitude.

Mechanism

In vitro, ezetimibe enhances lipid-droplet-to-mitochondria contact and improves ATP production and membrane potential in a podocyte cell line (Kim et al., 2024, Alport syndrome model), and separately enhances sarcoplasmic-reticulum-to-mitochondria calcium transfer at nanomolar concentrations (Sander et al., 2021, in vitro). Both describe a supportive, not depleting, mechanism.

Counter-evidence held on record

All located evidence, human and preclinical, runs toward improved rather than impaired mitochondrial function; this should not be oversold as a benefit claim either, since none of these studies were designed to demonstrate a general clinical benefit from ezetimibe's mitochondrial effects, only a mechanistic parameter. Labeled myopathy/rhabdomyolysis, a real, labeled clinical adverse effect especially in statin combination, must never be re-labeled as "mitochondrial burden" or "CoQ10 depletion" on the consumer surface; that specific claim is already rebutted for ezetimibe in the Fails Verification table above. This entry is a context flag, not a deficiency finding, and does not support a mitochondrial-support supplement claim.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress markers

Yellow — Low

Direction: reverse direction (as labelled in the source) · Evidence in: Tier a

One human clinical trial and at least seven independent animal/in vitro studies located for this review found ezetimibe lowering oxidative stress markers across multiple tissue and disease models; no study located found ezetimibe increasing oxidative stress in a way attributable to nutrient depletion.

Full detail and limits

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · reverse-direction, human tier a

Limits on what this shows

  • Key negative/null findings: No study located, human or preclinical, found ezetimibe increasing oxidative stress markers. This is itself a finding worth stating plainly rather than omitting.
  • At-risk subgroups: None identified; if anything, subjects with high baseline oxidative stress showed the largest measured reduction in the one human trial located.

Regulatory status

Not addressed in the label; oxidative stress markers are not a labeled parameter.

Population evidence

Human (Kostapanos et al., Lipids, 2011): "Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress." Full sample size, exact markers, and statistics could not be independently retrieved beyond the title; the reported direction, reduction, is treated as a Tier A directional finding, not a quantified one, in this dossier.

Mechanism

Named across multiple preclinical studies, none independently opened beyond title/abstract for this review, each Tier B (animal/in vitro) for ezetimibe: Nrf2/antioxidant-response-element and unfolded-protein-response pathway up-regulation during ischemia-reperfusion (Peserico et al., 2020); AMPK/Nrf2/TXNIP pathway in cerebral ischemia (Yu et al., 2020); Akt/GSK-3beta pathway in endothelial cells (Qin et al., 2018); Nrf2/HO-1 pathway in renal ischemia-reperfusion (Chen et al., 2024); NRF2-mediated suppression of inflammation in diabetic retinopathy (Cheng et al., 2026). These are consistently protective, antioxidant-pathway-activating mechanisms, not depleting ones.

Counter-evidence held on record

None of the located preclinical studies used ezetimibe alone as a chronic, real-world oral therapy in the dose and population most relevant to routine hyperlipidemia treatment; several used injury models (ischemia-reperfusion, spinal cord injury, intermittent hypoxia) designed to stress-test a protective hypothesis, which can inflate apparent benefit relative to ordinary use. This is a limitation on the strength of the reverse-direction signal, not a reason to discard it. This is a pharmacological antioxidant-pathway effect of the drug itself, not evidence of a nutrient such as vitamin E or C being spared or restored, and must not be used to imply ezetimibe corrects or prevents nutrient-related oxidative damage.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Yellow — Low

Direction: reverse direction (as labelled in the source) · Evidence in: Tier b animal only, reverse direction

The only drug-specific iron evidence located is a single mouse study finding ezetimibe increased, not decreased, hepatic iron levels; this is a Tier B, reverse-direction signal, and the mechanism appears distinct from the NPC1L1/fat-soluble-vitamin pathway responsible for this dossier's existing vitamin K finding.

Full detail, limits and 1 references

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · tier b animal only, reverse direction

Limits on what this shows

  • Key negative/null findings: No human iron-deficiency or iron-excess finding was located. Structured searches combining ezetimibe with ferritin, hemoglobin, and erythrocyte parameters each returned zero results.
  • At-risk subgroups: None established; the only located study used a high-fat-diet mouse model with dietary iron manipulation, not a subgroup that maps cleanly onto a human patient population.

Regulatory status

Label does not mention iron, ferritin, hemoglobin, or hematocrit.

Population evidence

Animal (Kishino et al., Journal of Pharmacology and Experimental Therapeutics, 2013), "Ezetimibe increases hepatic iron levels in mice fed a high-fat diet." Mice were fed a high-fat diet with or without supplemental iron and treated with ezetimibe. Full quantitative results (magnitude, hepcidin/ferritin detail) could not be independently retrieved beyond the title and search-listing description; the direction, increase rather than deficiency, is the load-bearing fact carried into this entry. No corresponding human study was located.

Mechanism

Not the same transporter this dossier's vitamin K finding runs through. NPC1L1 mediates intestinal uptake of cholesterol, plant sterols, and fat-soluble vitamins via mixed micelles; dietary iron is absorbed through a separate route (DMT1 at the apical enterocyte membrane, exported via ferroportin, regulated by hepcidin). The more plausible link between ezetimibe and hepatic iron is indirect, through ezetimibe's effect on hepatic lipid handling, rather than a direct NPC1L1-mediated iron-absorption effect. This mechanistic distinction was actively checked, given the superficial similarity to the fat-soluble-vitamin pathway, and no direct evidence of NPC1L1-mediated iron transport was found; see the Overlap map below.

Counter-evidence held on record

No second animal or any human study was located to confirm or contradict this single mouse finding; it stands alone. This dossier's fat-soluble-vitamin mechanism was specifically checked as a possible shared pathway and ruled unlikely to be the operative mechanism, since iron does not use the NPC1L1 transporter. This is not an iron-deficiency finding and must never be presented as one; if anything, the single located data point runs toward iron accumulation, not iron loss, and supplementation is not addressed by this entry in either direction.

Copper

Not graded — disclosed evidence gap

See study details

No Tier B or C evidence and no circulating consumer claim were located connecting ezetimibe to copper status in either direction; this is printed as a gap in the evidence base, not as reassurance of safety.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded · evidence gap

Limits on what this shows

  • Key negative/null findings: Not applicable; no studies exist to report a null result from.
  • At-risk subgroups: None identified.
  • Why no grade: Both conditions for an ungraded entry are met: no Tier B/C evidence of any kind was located, and no circulating consumer claim linking ezetimibe to copper was found to rebut. Per this dossier's governance framework, that combination receives no color and no governance state.

Regulatory status

Label does not mention copper, ceruloplasmin, or any copper-related parameter.

Population evidence

None located. Structured PubMed searches combining "ezetimibe" with "copper," "copper homeostasis," and related terms returned zero results.

Mechanism

Copper is absorbed intestinally via CTR1 and related transporters, a pathway distinct from the NPC1L1 sterol transporter ezetimibe blocks. No mechanistic reason to expect an effect was identified, and none was found in the literature search performed.

Counter-evidence held on record

Any drug-specific human, animal, or in vitro study directly measuring copper status, ceruloplasmin, or copper-dependent enzyme activity in ezetimibe-treated subjects, or a circulating consumer claim specific enough to evaluate and rebut. Absence of evidence is not evidence of absence. This gap must be presented to the reader as an open question, not as a clean bill of health.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome

Orange — Moderate

See study details

A 12-week randomized, open-label human trial found ezetimibe significantly increased the relative abundance of Fusobacterium, with no significant change in overall microbial diversity or fecal short-chain fatty acids; this is a real, drug-specific, bounded compositional signal, not evidence of a collapsed or dysfunctional microbiome.

Full detail and limits

What the grade means here: at least one Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, defined subgroup, or functional rather than circulating marker). orange · bounded to one taxon, open-label active-comparator design

Limits on what this shows

  • Key negative/null findings: Both the human and mouse studies found fecal SCFA output unchanged, the functional readout most directly tied to microbiome-dependent host effects. The human study's own authors concluded the intervention had "limited effect on the overall gut microbial community and their metabolites."
  • At-risk subgroups: None established. The human cohort was specifically overweight/obese with dyslipidemia; confounding by indication is presumed and not excluded. This was an open-label, active-comparator (orlistat) and before/after design with no untreated control arm within the trial, and participants were not blinded and may have altered diet or behavior during the 12-week intervention independent of the drug itself; the trial cannot separate a direct drug effect from a diet-, weight-, or lipid-change-mediated effect.

Regulatory status

Label does not address gut microbiota.

Population evidence

Human, randomized controlled open-label trial (Jin et al., Frontiers in Pharmacology, 2021): 174 volunteers screened, 85 with overweight/obesity and dyslipidemia enrolled across orlistat and ezetimibe arms; the ezetimibe arm enrolled 31 participants, 26 completed 12 weeks. Alpha diversity was unchanged before versus after treatment (p>0.05). Fusobacteria increased significantly at the phylum and genus level (p<0.05); 71.3% of operational taxonomic units were shared before and after treatment. Fecal short-chain fatty acids were not significantly altered (p>0.05 for all types measured). Ezetimibe significantly lowered triglycerides, total cholesterol, and LDL cholesterol in the same cohort.

Mechanism

Not fully established in humans. A companion mouse study (Jin et al., Frontiers in Microbiology, 2022), 8 weeks of ezetimibe 10 mg/kg/day in high-fat-diet mice, found reduced Proteobacteria and Desulfovibrio and increased Bacteroides, alongside a decline in alpha-diversity indices (ACE, Chao1, observed OTUs) relative to untreated high-fat-diet controls; SCFAs were unchanged. The mouse and human findings do not point in one consistent direction (reduced Desulfovibrio, a sulfate-reducing genus, is generally read as favorable; the human alpha-diversity finding was null while the mouse alpha-diversity finding declined), and no causal mechanism specific to ezetimibe reshaping gut flora, rather than reflecting the underlying metabolic change or concurrent diet, has been established.

Counter-evidence held on record

No diversity loss and no SCFA change in either species is the most direct evidence against a broad microbiome-disruption claim; the mouse study's declining alpha-diversity indices are the one point of tension with the human null result and are recorded rather than reconciled. This is a description of a measured compositional shift in a specific, confounded population, not an established "gut health risk," and must not be used to suggest probiotic or prebiotic supplementation is indicated; no professional guideline reviewed for this dossier recommends microbiome monitoring or intervention for patients on ezetimibe.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery and utilization

Yellow — Low

Direction: reverse direction (as labelled in the source)

No study located measured ezetimibe's effect on hemoglobin, erythrocytes, or blood oxygen-carrying capacity in either direction; where oxygen handling was measured at the cellular/mitochondrial level, ezetimibe was associated with increased, not reduced, oxygen consumption.

Full detail and limits

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · split evidence, reverse direction where present

Limits on what this shows

  • Key negative/null findings: No study located found reduced oxygen consumption, reduced tissue oxygenation, or any hemoglobin/erythrocyte abnormality attributable to ezetimibe.
  • At-risk subgroups: None established for either component.

Regulatory status

Label does not mention hemoglobin, hematocrit, erythrocytes, or oxygen consumption/delivery.

Population evidence, delivery component

None located. Structured searches combining ezetimibe with hemoglobin, erythrocyte, hematocrit, and anemia/ferritin terms each returned zero results; this component of the category is an evidence gap, not a null finding, and is reported as such.

Population evidence, utilization component

Human (Hernandez-Mijares et al., Atherosclerosis, 2016) measured mitochondrial oxygen consumption, alongside reactive oxygen species and membrane potential, in polymorphonuclear leukocytes of hypercholesterolemic patients on simvastatin, ezetimibe, or the combination, reporting improved (increased) mitochondrial parameters; full quantitative detail could not be independently verified beyond the abstract-level summary located. Animal (Bracht et al., Basic & Clinical Pharmacology & Toxicology, 2016), isolated perfused rat liver: basal oxygen consumption was 22% higher in treated animals than controls; this study used a combined ezetimibe/simvastatin exposure, so the ezetimibe-specific contribution cannot be isolated from the statin's own, separately documented, mitochondrial effects.

Mechanism

Consistent with the Mitochondrial function entry above: enhanced lipid-droplet-mitochondria contact and calcium-transfer mechanisms reported elsewhere in this review would plausibly increase, not decrease, cellular oxygen utilization. No mechanism for impaired oxygen delivery, for example via anemia or hemoglobin synthesis, was identified or hypothesized in any source located.

Counter-evidence held on record

The rat liver study used a combination exposure, not ezetimibe alone, which limits how much of the 22% oxygen-consumption increase can be attributed to ezetimibe specifically rather than to simvastatin or to their combination; this limitation is carried forward rather than resolved. This entry must not be read as ezetimibe improving oxygen delivery to tissues, a claim no study located actually tested; it describes a cellular-level, mechanistic oxygen-consumption signal only, and the blood-level delivery question remains genuinely open.

ATP production

Yellow — Low

Direction: reverse direction (as labelled in the source) · Evidence in: Tier b in vitro only, reverse direction

The only direct ATP-production evidence located for ezetimibe is an in vitro study in Alport-syndrome podocytes showing improved ATP production alongside enhanced lipid droplet-mitochondria contact; combined with this dossier's existing finding that ezetimibe does not lower plasma coenzyme Q10, there is no drug-specific evidence of impaired ATP synthesis to report.

Full detail and limits

What the grade means here: mechanistic plausibility only, or class extrapolation without drug-specific human data; also used for reverse-direction signals and context flags. yellow · tier b in vitro only, reverse direction

Limits on what this shows

  • Key negative/null findings: No human or animal study measuring ATP production or output in ezetimibe-treated subjects was located in either direction, beyond the single disease-model in vitro study above; no evidence of impaired ATP synthesis was found anywhere in the sources reviewed.
  • At-risk subgroups: None established in a general population; the only positive signal comes from a genetic kidney-disease cell model, not from ordinary hyperlipidemia patients.

Regulatory status

Label does not address ATP, coenzyme Q10, or cellular energy metabolism.

Population evidence

In vitro (Kim et al., International Journal of Molecular Sciences, 2024): in a podocyte cell-culture model of Alport syndrome, ezetimibe enhanced lipid-droplet-to-mitochondria contact formation, improved fatty acid transfer, reduced lipotoxicity, and improved ATP production and mitochondrial membrane potential. This is a disease-model cell line, not a general human or animal system, and the finding should not be generalized beyond that context.

Mechanism

The most direct upstream link to ATP production this dossier can draw on is coenzyme Q10, an electron-transport-chain cofactor; this dossier's existing Fails Verification entry already establishes, from a randomized trial in 72 healthy men, that ezetimibe monotherapy does not significantly change plasma CoQ10 (0.99 to 0.95 mg/L, not significant), unlike simvastatin. No mevalonate-pathway mechanism connects ezetimibe to reduced ATP synthesis. The Kim et al. in vitro mechanism (lipid droplet-mitochondria contact) is a distinct, disease-model-specific pathway not previously described in this dossier.

Counter-evidence held on record

The CoQ10 null-finding trial (Berthold et al., 2006) is the closest thing to a direct, general-population ATP-pathway test available for ezetimibe, and it found no effect in either direction; it is treated here as the load-bearing counter-evidence against any ATP-depletion hypothesis for ezetimibe. The Alport-podocyte finding must not be generalized into an "ezetimibe boosts energy" or ATP-support supplement claim for ordinary patients; it describes a specific disease-model mechanism, and this dossier makes no dosing or supplement recommendations.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Coenzyme Q10

    Where it comes from: Generic "cholesterol medication depletes CoQ10" consumer content, sourced from statins' effect on the mevalonate pathway and loosely applied to any lipid-lowering drug.

    Why it fails: Ezetimibe blocks intestinal NPC1L1, not hepatic HMG-CoA reductase, so it never touches the mevalonate pathway that produces CoQ10. A randomized trial in 72 healthy men found ezetimibe monotherapy did not significantly change plasma CoQ10 (0.99 to 0.95 mg/L, not significant) while simvastatin alone (0.99 to 0.82 mg/L, p=0.0002) and the combination (0.99 to 0.70 mg/L, p<0.0001) both did.

  • Fat-soluble vitamins A/D/E/K, framed with bile-acid-sequestrant-level certainty

    Where it comes from: Some general references group any cholesterol-lowering agent with bile acid sequestrants such as cholestyramine, which are well documented to bind fat-soluble vitamins in the gut and reduce their absorption.

    Why it fails: Ezetimibe's mechanism, NPC1L1 transporter blockade, is pharmacologically distinct from bile acid sequestration, and the label's own controlled 113-patient data found no meaningful vitamin A, D, or E reduction. Stated with sequestrant-level certainty, this claim fails for ezetimibe specifically; the narrower, mechanism-only version survives as the Yellow-tier entry above.

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Lab monitoring

    INR in anticoagulated patients

    Check INR when ezetimibe is started, stopped, or dose-adjusted in any patient on warfarin or another vitamin K antagonist, and again with any concurrent statin change, since the reported effect is stronger with concurrent statin use.

  • Drug-drug timing, not nutrient depletion

    Bile acid sequestrant separation

    The label directs dosing at least 2 hours before or 4 hours after a bile acid sequestrant such as cholestyramine; coadministration lowers ezetimibe's own exposure by about 55%. This is cholestyramine binding ezetimibe in the gut, not ezetimibe depleting a nutrient.

  • Drug-drug monitoring

    Cyclosporine coadministration

    Cyclosporine substantially raises ezetimibe exposure and vice versa; the label recommends monitoring cyclosporine concentrations when the two are used together.

  • Not currently indicated

    Routine fat-soluble vitamin panel

    No professional guideline or the drug's own trial data currently support routine vitamin A, D, E, or K testing for patients on ezetimibe alone. Testing remains a case-by-case clinical judgment, not a protocol-driven recommendation from this evidence base.

  • Distinct indication, not a deficiency context

    Homozygous familial sitosterolemia

    In this specific rare population, ezetimibe lowering plasma sitosterol (21% versus a 4% placebo rise) and campesterol (24% versus a 3% placebo rise) is the intended therapeutic effect, not a nutrient deficiency signal, and it does not generalize to ordinary hyperlipidemia patients.

  • Context

    Confounding by indication and diet

    Patients started on ezetimibe are usually also receiving separate dietary counseling for hyperlipidemia. Any nutrient change observed after starting the drug should be checked against diet history before being attributed to ezetimibe itself.

All references used above
  1. EZETIMIBE tablet, prescribing information. — DailyMed, U.S. National Library of Medicine, current label. Regulatory source for mechanism, pharmacokinetics, the 113-patient fat-soluble vitamin trial, and all labeled drug interactions.
  2. Effect of the inhibition of a cholesterol membrane transporter on vitamin D absorption: a double-blind randomised placebo-controlled study. — European Congress of Endocrinology 2015, conference abstract EP274. Randomized, placebo-controlled, 51 medical students, ezetimibe 10 mg/day for 5 days before a cholecalciferol challenge.Congress abstract; a fuller peer-reviewed manuscript with a matching title appears to exist in a paywalled journal (Bone) that was not independently opened, so only the abstract's own reported numbers are cited here.
  3. Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M. Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels. — Angiology, 2013. Prospective randomized open-label blinded-endpoint study, 50 patients with primary hypercholesterolemia, 12 weeks. Active-comparator design, no untreated arm.
  4. Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. — Heart and Vessels (Springer), retrospective cohort, 101 outpatients on warfarin who started ezetimibe, Kitasato University, October 2007-March 2015.
  5. Clinical Importance of Drug-Drug Interaction Between Warfarin and Prednisolone and Its Potential Mechanism in Relation to the Niemann-Pick C1-Like 1-Mediated Pathway. — Circulation Journal, J-STAGE. Describes an in vitro human NPC1L1-transfected cell uptake assay showing ezetimibe inhibits vitamin K1 uptake, and references the authors' own prior clinical warfarin-ezetimibe finding.
  6. Berthold HK, Naini A, Di Mauro S, et al. Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma: A Randomised Trial. — Drug Safety, 2006. Randomized parallel-group trial, 72 healthy men, three arms (ezetimibe 10 mg/day, simvastatin 40 mg/day, combination), 14 days, no placebo arm.
  7. Ezetimibe alters micelle structure and reduces Niemann-Pick C1-like 1-mediated absorption of vitamins E and K1 in Caco-2 cells. — In vitro cell-culture study.Full text blocked (403/paywall); cited by title and journal only, no statistics quoted.
  8. Inhibition of Niemann-Pick C1-like protein 1 by ezetimibe reduces uptake of deuterium-labeled vitamin D in mice. — Animal (mouse) study.Full text blocked (403/paywall); cited by title and journal only, no statistics quoted.
  9. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study. — Described via the American Society for Nutrition's own summary of the study; reports that genetically proxied NPC1L1 inhibition (the ezetimibe target, modeled through genetic variants, not actual drug exposure) was associated with higher serum calcium and vitamin A.Primary journal article blocked from direct access (robots.txt on ScienceDirect; CAPTCHA on the PMC copy). Cited via the publisher's own press summary; only the reported direction of association is used, no effect sizes or confidence intervals.
  10. Ezetimibe and warfarin interaction monograph. — Drugs.com professional interaction database, citing label language and a 2002 pharmacokinetic study in 12 healthy volunteers that found no significant effect of ezetimibe on warfarin bioavailability or prothrombin time.Secondary compilation; the underlying 2002 study was not independently opened.
  11. Drug-nutrient depletion chart. — Consumer circulating-claims audit: ezetimibe/Zetia is not listed anywhere in this chart. Statins are listed separately with a CoQ10 depletion claim.
  12. Can Medications Deplete the Nutrients Our Bodies Need? — Consumer circulating-claims audit: discusses cholesterol medications generically, attributes CoQ10 depletion to statins by name, and cites the Berthold ezetimibe/simvastatin study only in its reference list, not in the main claim text.
  13. Ezetimibe. — Wikipedia. Used only for the ATC code (C10AX09) and brand name confirmation, not for any clinical or evidentiary claim.
  14. Kostapanos MS, Spyrou AT, Tellis CC, et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. — Lipids, 2011. Human clinical trial, hypercholesterolemic subjects with elevated baseline oxidative stress.PMID individual page returned no retrievable full text/abstract for this review; cited from the PubMed search-listing snippet (title, journal, year, subject description) only. Sample size, exact markers, and statistics could not be independently verified.
  15. Peserico D, Stranieri C, Garbin U, et al. Ezetimibe Prevents Ischemia/Reperfusion-Induced Oxidative Stress and Up-Regulates Nrf2/ARE and UPR Signaling Pathways. — Antioxidants (Basel), 2020. Animal/in vitro study.Cited from PubMed search-listing snippet only; full text not independently opened.
  16. Yu J, Wang WN, Matei N, et al. Ezetimibe Attenuates Oxidative Stress and Neuroinflammation via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats. — Oxidative Medicine and Cellular Longevity, 2020. Animal study (rats).Cited from PubMed search-listing snippet only; full text not independently opened.
  17. Qin J, Wang LL, Liu ZY, et al. Ezetimibe Protects Endothelial Cells against Oxidative Stress through Akt/GSK-3beta Pathway. — Current Medical Science, 2018. In vitro study.Cited from PubMed search-listing snippet only; full text not independently opened.
  18. Chen Z, Wang K, He X, et al. Ezetimibe ketone protects against renal ischemia-reperfusion injury and attenuates oxidative stress via activation of the Nrf2/HO-1 signaling pathway. — Journal of Biochemical and Molecular Toxicology, 2024. Animal/in vitro study.Cited from PubMed search-listing snippet only; full text not independently opened.
  19. Cheng L, Cheng S, Zhu R, Xu G. Ezetimibe attenuates diabetic retinopathy via NRF2-mediated suppression of inflammation and oxidative stress. — Journal of Diabetes and its Complications, forthcoming 2026. Animal/in vitro study.Cited from PubMed search-listing snippet only; full text not independently opened.
  20. Kato R, Nishioka S, Nomura A, et al. Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia. — European Journal of Pharmacology, 2015. Animal study (mice), intermittent-hypoxia model.PMID individual page returned no retrievable full text/abstract; cited from PubMed search-listing snippet only.
  21. Hernandez-Mijares A, Banuls C, Rovira-Llopis S, et al. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia. — Atherosclerosis, 2016. Human clinical trial, hypercholesterolemic patients; measured mitochondrial oxygen consumption, reactive oxygen species, and membrane potential in polymorphonuclear leukocytes across simvastatin, ezetimibe, and combination arms.Full text blocked (paywall/403 on the publisher site; PMID page returned no retrievable content). Cited from the PubMed search-listing snippet and a related search-listing snippet quoting the measured parameters; exact sample size, per-arm results, and statistics could not be independently verified.
  22. Sander P, Feng Y, Schaks S, et al. Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca2+ uptake and suppress cardiac arrhythmogenesis. — British Journal of Pharmacology, 2021. In vitro study.Cited from PubMed search-listing snippet only; full text not independently opened.
  23. Kim JJ, et al. Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes. — International Journal of Molecular Sciences, 2024. In vitro study, podocyte cell-culture disease model.Cited from PubMed search-listing snippet only; full text not independently opened.
  24. Zheng Y, et al. Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction. — Frontiers in Pharmacology, 2023. In vitro/animal cancer model; cited only to explain why this finding is excluded from the general-population mitochondrial-function entry.Cited from PubMed search-listing snippet only; full text not independently opened.
  25. Kishino Y, Tanaka Y, Ikeda T, et al. Ezetimibe increases hepatic iron levels in mice fed a high-fat diet. — Journal of Pharmacology and Experimental Therapeutics, 2013. Animal study (mice), high-fat diet with and without supplemental iron.Full text blocked; PMID individual page and journal page (403) both returned no retrievable content, and repeated attempts hit rate limits on secondary sources. Cited from the original PubMed search-listing snippet only (title, authors, year, journal, and a one-line relevance description); quantitative magnitude and mechanism (hepcidin/ferritin detail) could not be independently verified.
  26. Jin J, Cheng R, Ren Y, et al. Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention. — Frontiers in Pharmacology, 2021. Human randomized controlled open-label trial, 174 screened, 85 enrolled with overweight/obesity and dyslipidemia; ezetimibe arm 31 enrolled, 26 completed 12 weeks.
  27. Jin J, Wang J, Cheng R, et al. Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota. — Frontiers in Microbiology, 2022. Animal study, 80 male C57BL/6J mice, four groups, 20 weeks total with 8-week drug intervention, ezetimibe 10 mg/kg/day.
  28. Bracht L, et al. [Effect of simvastatin/ezetimibe combination on hepatic oxygen consumption and metabolism in the isolated perfused rat liver]. — Basic & Clinical Pharmacology & Toxicology, 2016. Animal study, isolated perfused rat liver; combined ezetimibe/simvastatin exposure, not ezetimibe alone.Cited from PubMed search-listing snippet only; full text not independently opened. Combination-exposure design means the ezetimibe-specific contribution cannot be isolated.
  29. PubMed structured searches confirming absence of evidence. — Searches combining "ezetimibe" with "copper," "copper homeostasis," "hemoglobin," "erythrocyte," "hematocrit," and "ferritin"/"iron deficiency" each returned zero results as of the access date below; used to support the Copper ungraded entry and the delivery component of the Oxygen delivery/utilization entry.